fingolimod hydrochloride has been researched along with Leishmaniasis, Visceral in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexander, CE; Amante, FH; Best, SE; Bunn, PT; de Labastida Rivera, F; Engwerda, CR; Faleiro, RJ; Haque, A; James, KR; Kaye, PM; Montes De Oca, M; Mulherin, A; Sheel, M; Stanley, AC | 1 |
| Artemiadis, AK; Kolokythopoulos, D; Nikolaou, G; Papanastasiou, I; Tegos, N; Terentiou, A; Triantafyllou, N | 1 |
2 other study(ies) available for fingolimod hydrochloride and Leishmaniasis, Visceral
| Article | Year |
|---|---|
Tissue requirements for establishing long-term CD4+ T cell-mediated immunity following Leishmania donovani infection.
Topics: Animals; Antigens, Protozoan; CD4-Positive T-Lymphocytes; Dendritic Cells; Epitopes, T-Lymphocyte; Female; Fingolimod Hydrochloride; Immunologic Memory; Immunosuppressive Agents; Leishmania donovani; Leishmaniasis, Visceral; Liver; Lymphocyte Activation; Lymphoid Tissue; Mice; Mice, Knockout; Propylene Glycols; Sphingosine; Spleen | 2014 |
Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leishmaniasis, Visceral; Multiple Sclerosis | 2015 |